Drugs / [18F]THK-5351
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03112096 | May 2017 → Aug 2018 | Alzheimer disease | Asan Foundation | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03024944 | Dec 2017 → Jan 2019 | Alzheimer disease, diabetes mellitus | Columbia University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04572477 | Jun 2017 → Nov 2023 | vascular dementia | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02884492 | Jul 2016 → Jun 2017 | Alzheimer disease | William Charles Kreisl | Terminated | No outcome recorded |
| Phase 2 | NCT02656498 | Jan 2016 → Dec 2019 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Jae Seung Kim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-THK-5351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02884492 ↗ |
| Modality | Diagnostic / imaging agent | “18F-THK-5351 is a PET radioligand” NCT02884492 ↗ |
| Route | Intravenous | “an IV injection” NCT02656498 ↗ |